Gemina Laboratories Ltd. (GLABF)
OTC PINK OTC PINK Primary Summary
Gemina Laboratories Announces Private Placement
VANCOUVER, BC / ACCESSWIRE / November 13, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7)(OCTQB:GLABF) (the "Company" or "Gemina") is pleased to announce a non-brokered private placement offering (the "Offering") of up to 9,333,333 common shares in the capital of the Company (each, a "Share") at a price of $0.75 per Share.
Gemina Laboratories Ltd. (GLABF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Gemina Laboratories Ltd. ever had a stock split?
Gemina Laboratories Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Robert Crandall Greene CEO | OTC PINK Exchange | 368650107 CUSIP |
| CA Country | 6 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Gemina Laboratories Ltd. is a biotechnology firm immersed in the innovation, research, and development of in-vitro diagnostics focusing primarily on the Canadian market. With a foundational commitment to improving diagnostic solutions, the company pioneers in crafting rapid and reliable testing kits for infectious diseases. Since its inception in 2017, with its headquarters nestled in Burnaby, Canada, Gemina Laboratories has embarked on a mission to revolutionize the landscape of diagnostic testing through cutting-edge research and development strategies. This commitment extends to the establishment of a robust product pipeline aimed at enhancing the diagnosis of infectious respiratory diseases, thereby contributing significantly to public health management and response.
Products and Services
- Legio X (COVID-19 Rapid Antigen Test)
This innovatively designed testing kit is a hallmark of Gemina Laboratories’ dedication to fighting the global pandemic. Legio X utilizes the groundbreaking Gemina Surface Chemistry technology, aiming to deliver swift and accurate diagnosis of COVID-19 infections. This rapid antigen test stands as a testament to the company’s efforts in addressing the urgent need for accessible and reliable diagnostic tools amidst the health crisis.
- LEGIO X (Influenza AB Multiplex Lateral Flow Test)
Expanding its arsenal of diagnostic solutions, Gemina Laboratories has developed the LEGIO X for the efficient detection of Influenza A and B strains. This multiplex lateral flow test is engineered to offer precise and quick influenza diagnostics, leveraging the same innovative technology that powers the company’s COVID-19 rapid test. The development of LEGIO X underscores Gemina’s commitment to broadening its impact on respiratory disease diagnosis through the application of advanced diagnostic technologies.
The company is also ardently working on expanding its product pipeline with a focus on diagnosing a variety of infectious respiratory diseases. These development efforts are grounded in Gemina Laboratories’ vision to lead in the commercialization of diagnostic solutions that address a wide spectrum of global health challenges, emphasizing its role in advancing public health safety and disease management.
